Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006

K Smyth, J S Affandi, J C McArthur, C Bowtell-Harris, Anne M Mijch, K Watson, K Costello, Ian J Woolley, P Price, Steven Lodewyk Wesselingh, Catherine Cherry

Research output: Contribution to journalArticleResearchpeer-review

99 Citations (Scopus)


OBJECTIVES: The aim of the study was to describe the prevalence of and risk factors for HIV-associated sensory neuropathy (HIV-SN) in 2006 [the era of stavudine, didanosine and zalcitabine (dNRTI)-sparing highly active antiretroviral therapy (HAART)] and to compare our findings with data obtained in the same clinic in 1993 (pre-HAART) and 2001 (frequent use of dNRTI-containing HAART). METHODS: This was a cross-sectional comparative study using convenience sampling. HIV-positive adults attending a tertiary referral clinic over a 2-week period were screened for HIV-SN using the AIDS Clinical Trials Group screening tool. HIV-SN was defined as present if the patient had both neuropathic symptoms and abnormal signs. Demographic, clinical, laboratory and treatment data were considered as possible risk factors for HIV-SN, and results were compared with data obtained in the same clinic in 1993 and 2001. RESULTS: One hundred patients were screened. The prevalence of HIV-SN was 42 , which was unchanged since 2001 (44 ) despite a significant reduction in the use of dNRTIs. HIV-SN remained much more common than in 1993 (42 vs 13 ; P
Original languageEnglish
Pages (from-to)367 - 373
Number of pages7
JournalHIV Medicine
Issue number6
Publication statusPublished - 2007

Cite this